Metlife logo

MetLife Not Likely To Challenge FSOC Despite Questionable Analysis

The decision by the U.S. Treasury Department's Financial Stability Oversight Council (FSOC) to tag insurance company MetLife as a systematically significant institution was controversial. Now, Sterne Agee is adding fuel to a fire that will likely die out, as no further action from Met Life on the issue is expected.

In a research report today, Sterne Agee analysts John Nadel, Wesley Carmichael and Michael Ward concluded the FSOC report is “one-sided” and that it is “abundantly clear” the report “paid little attention to mitigating factors” MetLife . . .

SORRY!

This content is exclusively for paying members. Sign up here

If you are subscribed and having an account error please clear cache and cookies if that does not work email support@valuewalk.com or click chat


X
Saved Articles
X
TextTExtLInkTextTExtLInk

The Life and Career of Charlie Munger

Charlie is more than just Warren Buffett’s friend and Berkshire Hathaway’s Vice Chairman – Buffett has actually credited him with redefining how he looks at investing. Now you can learn from Charlie firsthand via this incredible ebook and over a dozen other famous investor studies by signing up below:

  • Learn from the best and forever change your investing perspective
  • One incredible tidbit of knowledge after another in the page-turning masterpiece of a book
  • Discover the secrets to Charlie’s success and how to apply it to your investing
Never Miss A Story!
Subscribe to ValueWalk Newsletter. We respect your privacy.

Are you an intelligent investor?

ValueWalkPremium is a website and newsletter for smart investors like yourself. We focus on the latest hedge fund industry news much of which is not in the public domain and obtained via our sources.

We also have 10 years of resources on how to use this information to better your investment process.

Sign up for  today for only a few dollars a day and get a 3 day no obligation trial with a targeted 20% discount coupon code.

Cancel anytime during trial and you are never charged.

Limited time offer: For first 50 subscribers

0